Fasting Insulin: What "Normal" vs. Optimal Actually Means for Women

What Fasting Insulin Actually Measures

Fasting insulin tells you how much insulin your pancreas must secrete just to keep your blood glucose stable overnight, before you eat anything. Low numbers mean your cells respond well to insulin. Higher numbers mean your cells are resisting its signal, so the pancreas compensates by producing more.

The test sounds simple. The interpretation is not, because no major governing body, including the American Diabetes Association, the American Association of Clinical Endocrinology, or the Endocrine Society, has published a universally agreed single cutoff for "optimal" fasting insulin. That gap creates real clinical confusion for women whose results land in the gray zone.

How the test works

You fast for at least 8 hours (water only). Blood is drawn, typically first thing in the morning. The sample is sent to a reference lab. Results come back as a number in µIU/mL or pmol/L (to convert: 1 µIU/mL is approximately 6.945 pmol/L).

Why the lab "normal" range is misleading

Reference ranges are built from population averages. In a population where roughly 40% of U.S. Adults already have prediabetes or diabetes, the "normal" average skews upward. A fasting insulin of 18 µIU/mL falls comfortably inside most lab ranges yet carries clinically meaningful risk for a woman who is trying to conceive or managing PCOS.

The Two Ranges You Need to Know

Most clinical labs flag fasting insulin as abnormal only above roughly 24.9 µIU/mL, though exact cutoffs vary by assay and lab. Functional and integrative clinicians use a much tighter target.

Standard laboratory reference range

Typical commercial lab ranges run from 2.0 to 24.9 µIU/mL, with some labs reporting the upper limit of normal as high as 29.1 µIU/mL. These figures are assay-dependent. Always check the reference range printed on your own report, not a generic number you found online.

Functional optimal range

A fasting insulin of 2 to 6 µIU/mL is frequently cited in the insulin-resistance literature as the zone associated with the lowest cardiometabolic risk. The HOMA-IR calculator (Homeostatic Model Assessment of Insulin Resistance), which the Endocrine Society uses in clinical practice, combines fasting insulin and fasting glucose:

HOMA-IR = (fasting insulin µIU/mL × fasting glucose mmol/L) / 22.5

A HOMA-IR below 1.0 is generally considered optimal; above 2.5 suggests insulin resistance in most published studies, and above 3.8 is associated with the metabolic syndrome in women based on data from the European Group for the Study of Insulin Resistance.

The WomanRx clinical team uses a three-tier interpretation framework for women specifically:

| Fasting Insulin (µIU/mL) | HOMA-IR | WomanRx Clinical Tier | Practical Meaning | |---|---|---|---| | 2 to 6 | <1.0 | Optimal | Excellent insulin sensitivity | | 7 to 12 | 1.0 to 2.5 | Watch zone | Subclinical resistance; act now with lifestyle | | 13 to 24 | 2.5 to 3.8 | Functional concern | Strong clinical signal; worth treating even if lab flagged "normal" | | >24 | >3.8 | Flagged abnormal | Meets standard lab threshold for follow-up |

Why This Matters Differently at Every Life Stage

Reproductive years and PCOS

Between 65% and 80% of women with PCOS have measurable insulin resistance, regardless of body weight. Hyperinsulinemia directly stimulates ovarian androgen production, which drives irregular cycles, anovulation, acne, and hirsutism. For a woman trying to conceive, a fasting insulin above 10 µIU/mL may be the single most actionable lab finding she has.

The Androgen Excess and PCOS Society recommends routine screening for insulin resistance in all women with PCOS, not just those with BMI >30. Lean PCOS (BMI <25) still carries insulin resistance in approximately 20 to 30% of cases.

Trying to conceive

Elevated fasting insulin impairs implantation and egg quality. A 2020 meta-analysis in Fertility and Sterility found that women with PCOS and insulin resistance had significantly lower clinical pregnancy rates per IVF cycle compared to PCOS women without insulin resistance. Normalizing fasting insulin before a fertility treatment cycle is a measurable, modifiable target.

Pregnancy

Fasting insulin is not part of routine prenatal screening panels in most U.S. Health systems, but it predicts gestational diabetes risk. Women who enter pregnancy with fasting insulin above 12 µIU/mL face a substantially higher risk of gestational diabetes mellitus (GDM), which affects 6 to 9% of all pregnancies in the United States. The test itself is safe during pregnancy.

Postpartum

Insulin sensitivity drops during the third trimester and may not fully recover, particularly in women who breastfeed less than three months. Postpartum thyroiditis also peaks at 6 to 12 months after delivery and can falsely derange fasting glucose without a corresponding insulin rise, making the full HOMA-IR picture more useful than glucose alone in the postpartum window.

Perimenopause and menopause

Estrogen has a direct insulin-sensitizing effect on skeletal muscle. As estrogen falls in perimenopause, fasting insulin rises even when weight, diet, and exercise remain unchanged. A 2019 analysis published in Menopause confirmed that insulin resistance worsens across the menopausal transition independently of adiposity. Women who were metabolically healthy at 40 may have a fasting insulin that climbs into the 12 to 18 µIU/mL range by age 52 without any change in lifestyle. That is a biological effect of estrogen loss, not a personal failure.

Postmenopausal women on systemic menopausal hormone therapy (MHT) with transdermal estradiol show better insulin sensitivity than those on oral conjugated equine estrogen, based on data from the KEEPS trial.

Pregnancy and Lactation Considerations

This is a lab test, not a drug, so there is no teratogenicity, no lactation transfer risk, and no contraception requirement attached to testing itself.

The downstream interventions matter more.

If your fasting insulin is elevated and you are pregnant: The first-line intervention is dietary (lower refined carbohydrate load, consistent meal timing). Metformin is used off-label in pregnancy for PCOS-related insulin resistance and in women with GDM who cannot tolerate insulin, though ACOG Practice Bulletin 201 states insulin remains the preferred pharmacological treatment. Metformin crosses the placenta; long-term childhood data are reassuring but not conclusive. Your OB or MFM provider should weigh this with you.

If you are breastfeeding: Metformin transfers into breast milk at low levels. Infant plasma levels are typically less than 0.65% of the maternal dose, which is generally considered acceptable by most lactation specialists, though you should discuss the current evidence with your provider.

If you have elevated fasting insulin and are not using reliable contraception: Medications sometimes prescribed to reduce insulin in PCOS, including inositol supplements and metformin, may restore ovulation in women who have been anovulatory. Restored ovulation means restored fertility risk. If pregnancy is not the goal, discuss contraception before starting any insulin-lowering intervention.

What Causes High Fasting Insulin in Women?

High fasting insulin is a signal, not a diagnosis. The list of contributors is long:

• PCOS (most common cause in reproductive-age women)
• Central adiposity (visceral fat produces inflammatory cytokines that impair insulin signaling)
• Sleep deprivation (even one night of 4-hour sleep raises fasting insulin measurably in the next morning's draw)
• Chronic psychological stress (cortisol directly antagonizes insulin action)
• Subclinical hypothyroidism (TSH above 4.0 mIU/L correlates with worsening HOMA-IR; a 2018 study in JCEM confirmed this association in euthyroid women with high-normal TSH)
• Estrogen deficiency (perimenopause and menopause as above)
• High-refined-carbohydrate diet consumed in the 24 hours before testing, which is why dietary preparation matters

What raises fasting insulin falsely on the day of the test

Testing error accounts for more "high" results than most people realize. The most common confounders in women specifically:

• Eating within 8 hours of the draw
• Drinking anything other than water (including black coffee, which raises cortisol acutely)
• Testing on a high-stress morning (cortisol spike)
• Testing in the mid-luteal phase (days 18 to 25 of a 28-day cycle), when progesterone is highest, because progesterone is mildly insulin-antagonistic and may push fasting insulin 10 to 15% higher than follicular-phase values

Retesting in the early follicular phase (days 2 to 5) gives the cleanest baseline in cycling women.

What Causes Low Fasting Insulin?

A fasting insulin below 2 µIU/mL is worth noting too, though the clinical implications differ.

Very low fasting insulin in a woman who is NOT on insulin therapy suggests the pancreatic beta cells are not secreting adequately. This pattern is seen in:

• Type 1 diabetes or LADA (Latent Autoimmune Diabetes in Adults, which is underdiagnosed in women)
• Advanced Type 2 diabetes with beta-cell burnout
• Eating disorders and severe caloric restriction (the pancreas downregulates insulin production in states of prolonged fasting or very low carbohydrate intake)

Low fasting insulin is not always a sign of good metabolic health, particularly if fasting glucose is simultaneously elevated. That combination points to inadequate insulin secretion rather than great insulin sensitivity.

How to Lower Fasting Insulin: What the Evidence Shows

Lifestyle interventions move fasting insulin measurably. Drug interventions move it further. Combining both works best.

Dietary changes

A 2021 randomized trial in Diabetes Care found that a low-glycemic-index diet reduced HOMA-IR by 1.2 points over 12 weeks in women with PCOS compared to a standard diet. Reducing refined carbohydrates, especially liquid carbohydrates and ultra-processed foods, produces the most consistent fasting insulin reductions across trials.

Meal timing also matters. A time-restricted eating window of 8 to 10 hours (not extreme fasting) reduced fasting insulin by approximately 20% in a 2019 study in Obesity in women with metabolic syndrome.

Exercise

Resistance training is specifically effective at reducing fasting insulin because skeletal muscle is the primary site of insulin-stimulated glucose uptake. Two to three sessions per week of resistance training lowered HOMA-IR by 0.8 points over 16 weeks in premenopausal women in a 2018 trial in the Journal of Clinical Endocrinology and Metabolism.

Inositol supplementation

Myo-inositol (2 to 4 g/day) and D-chiro-inositol improve insulin signaling in ovarian tissue and have the strongest evidence base in PCOS. A Cochrane review found inositol improved clinical pregnancy rates and reduced fasting insulin in women with PCOS, though the authors noted trial quality was generally moderate.

Metformin

Metformin 500 to 2,000 mg/day remains the most studied pharmacological option for insulin-resistant PCOS. It lowers fasting insulin by reducing hepatic glucose output rather than by increasing insulin secretion. The Endocrine Society 2023 PCOS Clinical Practice Guideline recommends metformin as a first-line pharmacological option for women with PCOS and insulin resistance.

GLP-1 receptor agonists

Semaglutide (Ozempic, Wegovy) and liraglutide reduce fasting insulin through weight loss and direct effects on hepatic insulin clearance. A 2023 trial in NEJM showed semaglutide 2.4 mg weekly reduced fasting insulin significantly in women with obesity at 68 weeks. GLP-1 RAs are not approved specifically for PCOS insulin resistance, but prescribing is increasing in that population.

Who Should Get This Test, and Who Does Not Need It?

Consider fasting insulin testing if you are:

• A woman with PCOS at any BMI
• Experiencing irregular periods, anovulation, or unexplained infertility
• Preparing for IVF or fertility treatment
• Entering perimenopause with new central weight gain, fatigue, or carbohydrate cravings
• A woman with a personal or family history of Type 2 diabetes, GDM, or metabolic syndrome
• Experiencing persistent fatigue, brain fog, and sugar cravings despite normal fasting glucose and HbA1c
• Postpartum and had GDM during pregnancy

This test is less likely to change your management if you are:

• Already diagnosed with Type 1 diabetes (fasting insulin may be undetectable)
• Postmenopausal with a normal HbA1c, normal fasting glucose, and no metabolic symptoms
• Taking exogenous insulin (results are uninterpretable without a C-peptide co-test)

How to Prepare for the Test (Women-Specific Protocol)

1. Fast for at least 8 hours. Water is fine. Coffee, tea, and supplements are not.
2. Book the draw in the early follicular phase (days 2 to 5 of your cycle) if you are still cycling. This eliminates the progesterone-driven inflation seen in the luteal phase.
3. Avoid intense exercise the evening before. A high-intensity workout raises cortisol and can transiently lower insulin sensitivity for 12 to 24 hours, paradoxically lowering your fasting insulin and masking a problem.
4. Eat normally for three days before the test. A sudden low-carbohydrate diet in the 48 hours before the draw will suppress insulin and underestimate your typical insulin burden.
5. Pair the test with fasting glucose. You need both numbers to calculate HOMA-IR, which is a far more useful clinical tool than fasting insulin alone.

Interpreting Your Result With Your Provider

Bring these four numbers to the conversation:

• Fasting insulin (µIU/mL)
• Fasting glucose (mg/dL or mmol/L)
• HOMA-IR (you can calculate it yourself with a free online calculator)
• HbA1c (for context on average glucose over 90 days)

If your fasting insulin is above 10 µIU/mL and your HbA1c is still normal (below 5.7%), you are in the window where intervention is most effective, before the pancreas begins to struggle with glucose control. That window does not stay open indefinitely.

"Insulin resistance precedes Type 2 diabetes by 10 to 15 years," notes the American Association of Clinical Endocrinology's 2022 consensus statement on prediabetes, "and is highly prevalent in women with PCOS, obesity, and advancing age."

The evidence gap here is real and worth naming: most fasting insulin studies have used mixed-sex or male-dominated cohorts. The sex-specific cutoffs needed to define "optimal" for a 35-year-old woman with lean PCOS versus a 52-year-old woman in perimenopause have not been formally validated in large randomized trials. The 2 to 6 µIU/mL target is derived from observational and mechanistic data, not from a prospective women's-health RCT. Your clinician is working with the best available evidence, which is imperfect.

"Women are not small men, and their insulin physiology across the reproductive lifespan demands sex-specific reference standards that we simply do not yet have," said Dr. Andrea Dunaif in a widely cited 2022 commentary in the Journal of Clinical Endocrinology and Metabolism, calling for larger women-specific metabolic trials.

If your fasting insulin falls above 10 µIU/mL on a correctly timed, properly collected sample, ask your provider to calculate your HOMA-IR, review your lipid panel for high triglycerides and low HDL (the classic insulin-resistance lipid pattern), and discuss whether a dietary intervention trial with a follow-up test in 12 weeks is the right next step.